Ausgabe 4/2019
Inhalt (15 Artikel)
Open Access
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
Murali Kesavan, Toby A. Eyre, Graham P. Collins
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
Ipsita Pal, Maryam Safari, Marko Jovanovic, Susan E. Bates, Changchun Deng
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly
Yasir Khan, Elizabeth A. Brem
B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Mantle Cell Lymphoma: Which Patients Should We Transplant?
James N. Gerson, Stefan K. Barta
CART and Immunotherapy (M Ruella and P Hanley, Section Editors)
Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus
Wei Jiang, Barbara Withers, Gaurav Sutrave, Leighton E. Clancy, Michelle I. Yong, Emily Blyth
Open Access
CART and Immunotherapy (M Ruella and P Hanley, Section Editors)
Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges
Alexandros Nianias, Maria Themeli
CART and Immunotherapy (M Ruella and P Hanley, Section Editors)
Overcoming Challenges in Process Development of Cellular Therapies
Steven L. Highfill, David F. Stroncek
CART and Immunotherapy (M Ruella and P Hanley, Section Editors)
Towards Automated Manufacturing for Cell Therapies
David Smith, Thomas R. J. Heathman, Alex Klarer, Courtney LeBlon, Yasuhiko Tada, Brian Hampson
CART and Immunotherapy (M Ruella and P Hanley, Section Editors)
Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
Gerald P. Linette, Beatriz M. Carreno
Chronic Lymphocytic Leukemias (N Jain, Section Editor)
Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia
Krish Patel, John M. Pagel
Chronic Lymphocytic Leukemias (N Jain, Section Editor)
Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL
Adam S. Kittai, Matthew Lunning, Alexey V. Danilov
Myeloproliferative Neoplasms (B Stein, Section Editor)
The Rationale for Immunotherapy in Myeloproliferative Neoplasms
Lucia Masarova, Prithviraj Bose, Srdan Verstovsek
Health Economics (N Khera, Section Editor)
Emerging Role of Integrative Medicine in Hematologic Malignancies: a Literature Review and Update on Current Trends in Complementary Medical Practices in Hematologic Cancers
Onyemaechi N. Okolo, Krisstina Gowin
Open Access
Chronic Myeloid Leukemias (M Mauro, Section Editor)
Is There a Role for Dose Modification of TKI Therapy in CML?
M. Copland
Myelodysplastic Syndromes (M Savona, Section Editor)
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS
Rami S. Komrokji